News

European Regulators Grant Orphan Drug Status to Protalix’s PRX-102 for Fabry Disease

The European Commission has granted Protalix BioTherapeutics’ experimental treatment PRX-102 (pegunigalsidase alfa) Orphan Drug Designation for the treatment of Fabry disease, the company recently announced. The decision follows a European Medicines Agency (EMA) recommendation in November 2017, which stated the therapy may be of “significant benefit” to Fabry…

Amicus Therapeutics Files for FDA Approval of Migalastat to Treat Fabry Disease

Amicus Therapeutics recently submitted a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) for its investigational oral medicine migalastat for treatment of patients 16 years and older with Fabry disease who have so-called “amenable” mutations. The NDA seeks migalastat’s approval in the U.S. as an alternative to intravenous enzyme…